BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33191863)

  • 1. Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.
    Wang Y; Dong F; Wan W; Zhang Z; Wang J; Wang H; Ke X
    Hematology; 2020 Dec; 25(1):424-432. PubMed ID: 33191863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platycodin D inhibits proliferation, migration and induces chemosensitization through inactivation of the NF-κB and JAK2/STAT3 pathways in multiple myeloma cells.
    Wu D; Zhang W; Chen Y; Ma H; Wang M
    Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1194-1200. PubMed ID: 31347196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
    Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
    Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
    Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C
    Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
    Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
    Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].
    Zhang XY; Bai QX; Huang GS; Zhao H; Chen JJ; Yang LJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):684-8. PubMed ID: 21729550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
    Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
    Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
    Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
    J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
    Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
    Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
    Wang H; Liu X; Xu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):531-7. PubMed ID: 18549623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
    Mark C; Warrick J; Callander NS; Hematti P; Miyamoto S
    Mol Cancer Res; 2022 Sep; 20(9):1456-1466. PubMed ID: 35604822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.
    Ramakrishnan V; Mager DE
    J Pharmacol Exp Ther; 2018 Jun; 365(3):734-751. PubMed ID: 29632237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.